Drugs / FAPI GA-68
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials | ||||||
| Phase 0 | NCT06455761 | Apr 2024 → Apr 2025 | neoplasm | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT06455735 | Mar 2024 → Dec 2025 | neoplasm | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT05952531 | Jul 2023 → Jul 2024 | idiopathic inflammatory myopathy | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase 0 | NCT05691894 | Nov 2022 → Nov 2023 | cancer | Affiliated Hospital of Jiangnan University | Unknown | No outcome recorded |
| Phase 0 | NCT05543954 | Sep 2022 → Dec 2025 overdue | lung neoplasm | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05400967 | Jan 2022 → Jan 2025 overdue | — | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05036759 | May 2021 → Aug 2023 | atherosclerosis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04514614 | Sep 2020 → Jan 2022 | arthritic joint disease | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04507932 | Aug 2020 → Jan 2022 | inflammatory bowel disease | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04596462 | Jun 2020 → Jun 2021 | SAPHO syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05121779 | Nov 2021 → Dec 2025 overdue | pulmonary fibrosis | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07062523 | Jul 2024 → Sep 2025 overdue | Sjogren syndrome | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05990998 | Nov 2022 → Aug 2023 | — | First Affiliated Hospital of Fujian Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT05275699 | Mar 2022 → Feb 2023 | keloid | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07083011 | Nov 2025 → Jul 2027 expected | diastolic heart failure | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT04023240 | Jul 2023 | cancer | Stanford University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase not applicable2 trials | ||||||
| — | NCT05499936 | Oct 2021 → Oct 2022 | adenoid cystic carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT05034146 | Feb 2021 → Dec 2025 overdue | cancer | Zhongnan Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT06740240 Comparator | Mar 2024 → Jun 2026 overdue | neoplasm | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FAPI GA-68 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650356 ↗ |
| Known as | 68Ga-FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04514614 ↗ |
| Known as | [68 Ga]Ga-FAPI | “Gallium-68-labelled fibroblast activation protein inhibitor ([68 Ga]Ga-FAPI) is a tumour-stromal imaging agent showing complementary value alongside fluorine-18...” PMID 40614035 ↗ Jul 2025 |
| Known as | Fapi-02 ga-68 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650356 ↗ |
| Known as | Fapi-2 ga-68 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650356 ↗ |
| Action | Inhibit | “gallium 68-labelled FAP inhibitor (68Ga-FAPI)” NCT05034146 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-FAPI as the imaging agent for positron emission tomography (PET)/computed tomography (CT)” NCT04023240 ↗ |
| Route | Intravenous | “68Ga-FAPI is administered intravenously (IV)” NCT04023240 ↗ |
| Target | FAP | “68Ga-FAPI that targets fibroblast activation protein (FAP)” NCT04596462 ↗ |